Clinical Trials
8
Active:3
Completed:5
Trial Phases
2 Phases
Phase 1:6
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Phase 2
2 (25.0%)A Single and Multiple Ascending Dose Study of COR588
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04920903
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: COR388 capsuleDrug: Placebo capsule
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 643
- Registration Number
- NCT03823404
- Locations
- 🇺🇸
Xenoscience, Inc., Phoenix, Arizona, United States
🇺🇸Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Banner Sun Health, Sun City, Arizona, United States
A Multiple Ascending Dose Study of COR388
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03418688
- Locations
- 🇺🇸
Pacific Research Network, San Diego, California, United States
🇺🇸Bioclinica Research, Orlando, Florida, United States
🇺🇸Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Study of COR388 HCl in Healthy Subjects
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03331900
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
News
No news found